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Abstract
Background: Targeted therapies are emerging treatment options for gastric cancer (GC). Patient-derived tumor
xenograft(PDX) models of GC closely retain the features of the original clinical cancer, offering a powerful tool for
preclinical drug efficacy testing. This study aimed to establish PDX GC models, and explore therapeutics targeting
Her2, MET(cMet), and FGFR2, which may assist doctor to select the proper target therapy for selected patients.
Methods: GC tissues from 32 patients were collected and implanted into immuno-deficient mice. Using
immunohistochemistry(IHC) and fluorescent in-situ hybridization (FISH), protein levels and/or gene amplification
of Her2, cMet and FGFR2 in those tissues were assessed. Finally, anti-tumor efficacy was tested in the PDX models
using targeted inhibitors.
Results: A total of 9 passable PDX models were successfully established from 32 gastric cancer xenograft donors,
consisting of HER2,cMet and FGFR2 alterations with percentages of 4(12.5%), 8(25.0%) and 1(3.1%) respectively.
Crizotinib and AZD4547 exerted marked antitumor effects exclusively in PDX models with cMet (G30,G31) and
FGFR2(G03) amplification. Interestingly, synergistic antitumor activity was observed in G03 (FGFR2-amplifed and cMet
non-amplified but IHC [2+]) with simultaneous treatment with Crizotinib and ADZ4547 at day 30 post-treatment.
Further in vitro biochemistry study showed a synergistic inhibition of the MAPK/ERK pathway. HER2,cMet and FGFR2
alterations were found in 17 (10.4%), 32(19.6%) and 6(3.7%) in a group of 163 GC patients, and cMet gene amplification
or protein overexpression(IHC 3+) was associated with poor prognosis.
Conclusions: These PDX GC models provide an ideal platform for drug screening and evaluation. GC patients with
positive cMet or FGFR2 gene amplification may potentially benefit from cMet or FGFR2 targeted therapies or
combined targeted therapy.
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Background
Gastric cancer (GC) is one of the most commonly diag-
nosed cancers and one of the leading cause of cancer
related deaths worldwide [1, 2]. Despite improvements
in surgery and chemotherapy, the prognosis of advanced
gastric cancer remains poor, with a five-year survival rate
of nearly 20% [3]. Over the past decade, targeted therap-
ies have greatly improved the outcomes of patients with
certain malignancies, including breast, colorectal, and
lung cancer, however, less progress has been made with
regard to gastric cancer [4–7]. Therefore, developing
new therapeutic approaches, particularly through the
use of targeted therapeutic agents, is crucial in gastric
cancer research.
One of the main obstacles that hamper progress in
therapeutic approaches is the lack of appropriate pre-
clinical models. Conventional cell-implanted xenograft
models are commonly used for the development of new
drugs. However, prolonged in vitro culture and possible
selection cause cell-implanted xenograft models to lose
the original molecular characteristics and heterogeneity
of primary tumors, which results in poor prediction of
the clinical tumor’s drug response [8]. In contrast to cell
line–derived xenografts, patient derived tumor xeno-
grafts(PDX) closely retain the histopathologic, genetic,
and phenotypic features of the patients’ original tumors
[8–10]. Recently, PDX models have been widely estab-
lished for certain tumors, including lung, colorectal,
breast, pancreatic, and gastric cancers [9, 11–14]. PDX
models are now becoming a powerful tool for the study
of tumor biology and the evaluation of anticancer drugs.
Approving trastuzumab for HER2-positive GC patients
represents a milestone in targeted therapy for gastric can-
cer [15]. Recently, ramucirumab(anti-VEGFR2 monoclo-
nal antibody) has been approved for advanced gastric
cancer as second-line treatment; however, the improved
overall survival by targeted therapy is still limited [16, 17].
Therefore, developing targeted therapeutic agents and in-
creasing the population benefiting from them is urgent in
gastric cancer research. MET(cMet) is a member of the
RTK family and plays a key role in tumor survival, growth,
angiogenesis, and metastasis [18]. A significant proportion
of gastric cancers display cMet overexpression and/or
gene amplification, and aberrant signaling of cMet
pathways in gastric cancer is correlated with advanced
tumor stage and poor prognosis [19]. The initial results
of preclinical and clinical studies assessing cMet inhibi-
tors such as onartuzumab and crizotinib were negative
[20, 21]. FGFR2 is another member of the RTK family
that regulates cellular proliferation, survival, migration
and differentiation [22].
Approximately 4-7% of gastric cancers show FGFR2
amplification, which may correlate with poor prognosis of
gastric cancer patients [23, 24]. A recent study revealed
that AZD4547(a selective FGFR kinase inhibitor) exerts
marked antitumor effects on GC xenografts carrying
FGFR2 gene amplification [25]. Thus, it has become in-
creasingly apparent that FGFR2 is a potential therapeutic
candidate for gastric cancer.
In this study, we successfully established nine PDX
models using thirty-two implanted GC samples from pa-
tients. Then, Her2, cMet, and FGFR2 gene copy number
and protein expression levels were assessed in a cohort
of 163 GC patients as well as in the 32 GC patients who
donated the xenografts. Finally, targeted therapy’s antitu-
mor efficacy was evaluated in PDX models.
Methods
Patients and tumor samples
Thirty-two tumor specimens were obtained at initial sur-
gery from 32 gastric patients at the Department of
Surgical Oncology, The First Affiliated Hospital, School
of Medicine, Zhejiang University. Written informed con-
sent was obtained from each patient, and the study was
approved by the hospital ethics committee. This study
also included a cohort of 163 patients with GC who re-
ceived a surgical resection of primary gastric cancer
from January 2010 to December 2011 at the Department
of Surgical Oncology, The First Affiliated Hospital,
School of Medicine, Zhejiang University. The only cri-
teria used for patient selection included the availability
of tumor tissue from primary gastric cancer and that of
survival data. Follow-up data were obtained by phone,
letter, and from the out-patient clinical database, after
written informed consent forms provided by all patients.
This retrospective study was approved by the institu-
tional review board of the First Affiliated Hospital of
Zhejiang University.
Cell lines and cell culture
The gastric cancer cell lines AGS, KATOIII, SNU5 were
purchased from Shanghai Institute for Biological Sciences,
Chinese Academy of Science in Sep 2016. The cell lines
were characterized by the provider using short tandem
repeat (STR) markers. All the cell lines used in this manu-
script were tested for mycoplasma contamination in Oct
2016 before setting up for the biochemistry study. Primary
GC cells were derived from the tumor excised from the
PDX model of G03. Briefly, primary cells were purified
with differential adhesion technique and grew in RPMI-
1640 medium with 20% fetal bovine serum.
Reagents
Anti-cMet(ab51067) and anti-Her2(ab134182) antibodies
were from Abcam (Cambridge, UK), p-Met antibody (Tyr
1365) (sc-3408), p-ALK antibody (Tyr 1586) (sc-109905),
p-Akt1/2/3 antibody (Ser 473)-R (sc-7985-R) and horse-
radish peroxidase-conjugated secondary antibodieswere
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purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, USA). Phospho-FGFR (tyr653/654,#3471), phosp
hor-p44/p42 MAPK (Erk1/2, #4370), total-Erk1/2 (#4960)
were purchased from Cell Signaling Technology. Trastu-
zumab was obtained from Roche, Inc. (Roche, USA), while
crizotinib and ADZ4547 were from Selleck Chemicals,
LLC (Houston, CA, USA).
Cell treatment and Western-blotting
GC cells were seeded at a density of 3 × 105 cells/mL in
RPMI-1640 medium containing 10% FBS and cultured
overnight. The cells were then incubated with 200nM/L
crizotinib or 30 nmol/L AZD4547 for 1 hour or with a
combo of both reagent for one hour before being lysed
in RIPA cell lysis buffer containing phosphatase and pro-
tease inhibitors(sigma). Each 20 μg of protein was loaded
onto SDS-PAGE gel; followed by electrophoresis and
transferred to polyvinylidene difluoride (PVDF) mem-
branes and probed with antibodies.
Xenograft models and treatment protocol
Four-to-six-week-old female BALB/c nude mice, pur-
chased from Shanghai Slac Laboratory Animal Corpor-
ation (Shanghai, China), were housed with regular 12/
12-hour light-dark cycle for at least three days before
the study. Animal care was carried out in accordance
with the Principles of Laboratory Animal Care (NIH
publication#85-23, revised in 1985). All experimental
protocols were approved by the Institutional Animal
Care and Use Committee of Zhejiang University (ap-
proval ID: SYXK[ZHE]2005-0072). Tumor specimens
were obtained at initial surgery from patients after writ-
ten informed consent as mentioned above. PDX gastric
carcinoma xenograft models were established as previ-
ously described [8, 12]. The tumors were subcutaneously
implanted into the flanks of mice under anesthesia with
isoflurane; xenograft growth was monitored at least
twice weekly by Vernier caliper measuring of the tumor
length (a) and width (b).At about 1500 mm3, tumors
were extracted for serial transplantation. Numerous
samples from early passages were stored in the tissue
bank, cryopreserved in liquid nitrogen, and used for
further experiments. Third generation xenografts (i.e.
the second mouse-to-mouse passage) were used for
experiments at tumor volumes of about 100-200 mm3.
Totally, 136 mice were used in this research. Mice with
third generation xenografts were randomized divided
into several groups (n = 5), including i) vehicle (DMSO
as vehicle); ii) AZD4547, daily 6.25 mg/kg oral adminis-
tration; iii) crizotinib, daily 50 mg/kg oral administra-
tion; iv) trastuzumab, weekly 20 mg/kg intraperitoneal
injection; v) daily 6.25 mg/kg AZD4547 + 50 mg/kg
crizotinib per os. All treatments were administered for
4 weeks, and the dosages were selected according to
previous reports [21, 25, 26]. Mouse weights and tumor
volumes were assessed daily, with tumor volume derived
as (length × width 2)/2. Relative tumor growth inhibition
(TGI) was determined by the following formula: TGI = 1
- T/C, where T/C represents the relative tumor growth
of compound-treated mice divided by that of control
mice. For tumor regression, in which the tumor volume
after treatment was smaller than the initial value before
dosing, the following equation was used: regression %
= 100 × (T0-Ti)/T0. T0 and Ti are tumor volumes in
the same group, measured at different time points, with
T0 representing the tumor volume on the day preced-
ing the first treatment and Ti the tumor volume at the
last measurement day after treatment.
Immunohistochemistry (IHC)
For immunohistochemical staining, four-micrometer
sections were obtained, dewaxed, rehydrated, and sub-
jected to antigen retrieval. After quenching endogenous
peroxidase activity and blocking nonspecific binding
sites, the sections were incubated with primary anti-
bodies against HER2 (1:100) and cMet (1:100) at 4 °C
for 12 h. This was followed by a 30-min incubation with
secondary antibodies. Detection was carried out using
the streptavidin-biotin peroxidase complex method
(LabVision, Fremont, CA, USA) and sections were ana-
lyzed under an optical microscope (Nikon, Tokyo Japan;
200×).Her2and cMet expression levels were graded ac-
cording to Hercep Test guidelines as follows: score 0, no
membrane staining or membrane staining in <10% of
tumor cells; score 1+, faint/barely perceptible partial
membrane staining in >10% of tumor cells; score 2+,
weak-to-moderate staining of the entire membrane in
>10%of tumor cells; score 3+, strong staining of the en-
tire membrane in >10% of tumor cells. Scores of 0 and1
+ were considered negative for overexpression, and
scores of 2+ and3+ considered positive. HER2 positive
cases were defined by IHC 3+ or IHC 2+ plus Her2
amplification [15]. MET overexpression cases were de-
fined by IHC 2+/3 + .All immunohistochemical slides
were reviewed by two independent pathologists.
Fluorescence in situ hybridization (FISH)
FISH was performed for HER2 and MET gene assessment
on 4 μm dewaxed and dehydrated FFPE sections using the
HER2/CEN 17 Dual Color Probe (ZytoLight, Cat#Z-
2020-20), MET/CEN 7 Dual Color Probe(ZytoLight,
Cat# Z-2087-200) and FGFR2/CEN10 Dual Color Probe
(ZytoLight, Cat# Z-2122-200) kits, according to the
manufacturer's instructions. Probes were co-denatured for
5 min at 80 °C on the slide and incubated overnight at
37 °C. Then, slides were washed with post-hybridization
wash buffer(0.5X SSC / 0.1% SDS) for 5 min at 37 °C, air-
dried, and counterstained with DAPI dissolved in an anti-
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fade mounting solution. Using a fluorescence microscope
equipped with appropriate filters, the hybridization signals
of labeled HER2 /cMet/FGFR2 genes appeared green;
those of CEN 17/ CEN 7/ CEN10 appeared orange. The
HER2 and cMet genes were considered amplified at
FISH signal ratios of HER2/CEP17 or cMet/CEN 7 of
≥2.0 [15, 24, 27]. FGFR2gene amplification was defined
as FGFR2/CEP10 ratio ≥2 or tight FGFR2 gene clusters
in ≥10% of the nuclei analyzed per tissue section [25].
Statistical analysis
Overall survival was measured from the surgery date to
death. The Kaplan–Meier method was used to estimate
survival distributions, the log-rank test to compare survival
distributions, and the Pearson’s chi-squared test or Fisher’s
exact test to assess differences between groups. Tumor
volume differences between groups were assessed using
two-tailed Student’s t-test or one-way ANOVA. P < 0.05
was considered statistically significant. Statistical analyses
were performed using the SPSS 16.0 software (SPSS, USA).
Results and discussion
Results
Patient characteristics and establishment of PDX models
Nine passable PDX models were established by im-
plantation of GC specimens from 32 patients into
immuno-deficient mice. Model passage success rates
of first, second, and third generations were 43.7%(14/
32),37.5%(12/32), and 28.1%(9/32), respectively. The
detailed characteristics of the patients are shown in
Table 1. No differences were observed in success rates of
model establishment and patient characteristics for differ-
ent genders, age groups, tumor stages, differentiation
statuses, Lauren classes and pre-surgery chemotherapy
administration, as shown in Table 1. The established
PDX models showed different latency periods (from
the day of implantation to palpable tumor) and tumor
growth curves (Fig. 1).
Her2, cMet and FGFR2 status in PDX models and GC patient
cohort
Of the 163 GC patients(detailed characteristics in
Additional file 1: Table S1) and 32 GC xenograft donors,
HER2 was positive(IHC3+ or FISH +) in 10.4%(17/
163)and 12.5%(4/32), respectively; cMet was overex-
pressed (IHC3+/2+) in 19.6%(32/163) and 25%(8/32),
respectively; the cMet gene was amplified in 4.3%(7/163)
and 9.4%(3/32), respectively, while FGFR2 gene amplifi-
cation was found in 3.7%(6/163) and 3.1%(1/32), respect-
ively (Table 2). Representative images of IHC and FISH
analyses of gastric cancer tumor tissues are provided in
Fig. 2. Patients with cMet protein IHC3+ or gene ampli-
fication had poorer survival rates compared with those
without IHC3+ or gene amplification (Fig. 3). FGFR2
gene amplification tended to reflect a lower survival rate
compared with FGFR2 non-amplificated GC patients, al-
though statistical significance was not reached (Fig. 3).
While evaluating Her2, cMet and FGFR2 status in PDX
models(≥1 generation, as shown in Table 3), a concord-
ance rate of Her2, cMet and FGFR2 status between
primary tumors from patients and PDX models of 92.9%
(13/14) was found. Only the G23 model with cMet IHC
3+/FISH(+) changed to cMet IHC 0/FISH(-), as shown
in Additional file 2: Figure S1.
Gastric cancer PDX model responses to different
molecularly targeted agents
The main purpose of PDX models is to provide a platform
for the evaluation of molecularly targeted agents. A total
of 9 passable PDX models were established, which har-
bored alterations of Her2,cMet, and FGFR2(Table 3).
Several tyrosine kinase inhibitors which target cMet or
FGFR2 pathways show marked antitumor efficacy in
gastric cancer; these include crizotinib(cMet TKI)and
AZD4547(FGFR2 TKI). cMet or FGFR2 gene amplifica-
tion seems to be a potential predictive biomarker for drug
sensitivity. In order to test the hypothesis that use of crizo-
tinib or AZD4547 could offer therapeutic benefits to GC
Table 1 Characteristics of GC patients who donated xenografts
for the PDX models























aP values are from Fisher’s exact test and were significant
at <0.05.undiff,undifferentiated
Wang et al. BMC Cancer  (2017) 17:191 Page 4 of 11
patients harboring cMet or FGFR2 amplification, PDX
models of G30 (cMet-amplified), G31(cMet-amplified),
G03 (FGFR2-amplifed and cMet non-amplified but IHC(2
+)), G01(both cMet and FGFR2 non-amplified) were
assessed in vivo (Fig. 4). Meanwhile, G05(positive for
Her2) was also selected for Her2-targeted therapy.We
next evaluated the antitumor activity of crizotinib,
AZD4547 and trastuzumab on PDX GC models. Crizo-
tinib(50 mg/kg/day), AZD4547 (6.25 mg/kg/day), trastu-
zumab (20 mg/kg/week) were administered, respectively,
for 4 weeks as described above. A significant tumor
growth inhibition was observed in G30 and G31(cMet-
amplified) after treatment with crizotinib, in contrast to
G03 and G01(cMet non-amplified) (Fig. 5a, b, d and e).
However, a statistically significant tumor growth inhibition
was observed in G03 (FGFR2-amplified)treated with
AZD4547, while only minimal to partial tumor growth in-
hibition was observed in G01 (FGFR2 non-amplified)
(Fig. 5a and b). Interestingly, a statistically significant
difference in tumor volume was obtained in G03 after
treatment with AZD4547 plus crizotinib at day 30 post-
treatment (Fig. 5b). Moreover, a marked tumor growth
inhibition was observed upon trastuzumab treatment of
G05 (Her2-positivy) but not G01 (Her2-negative) (Fig. 5c).
The gastric cancer cells derived from G03 PDX and
commercial gastric cancer cell line AGS, KATOIII,
SNU5, were assigned for further biochemistry study.
The indicated cells were treated by anti-FGFR2 or anti-
MET treatment ,or by a combo treatment of both inhibi-
tors. Total protein was extracted and subsequently sent
to Western-blotting study. In the G03 PDX derived cell,
which was positive for FGFR2, showed synergetic inhib-
ition of p-ERK expression by a combo treatment of
crizotinib and AZD4547, however, no obvious inhibition
of AKT was observed (Fig. 6). To determine whether the
synergetic effect was cMet or FGFR2 status dependent,
we did the same assay in GC cell lines with different
status of the two receptors. We also observed the syner-
getic inhibition of p-ERK expression in the KATOIII cell
which was positive of FGFR2 amplification, and in
the SNU5 cell which was positive of cMet expression
(Additional file 3: Figure S2). However, no synergetic
inhibiting effect was observed in AGS cell line which
was negative for both receptor expression (Additional
file 4: Figure S3).
Discussion
Mouse xenografts derived from prolonged in vitro
cultured cells have been the standard toolkit for cancer bi-
ologists for decades; however, the high failure rate of com-
pounds entering clinical trials indicates a low clinical
predictive power of traditional tumor model systems.
Compared with cell line derived xenografts, patient de-
rived tumor xenografts models closely retain the histo-
pathologic, genetic and phenotypic features of patients’
original tumors, and could better predict drug efficacy in
humans [8–10]. In the last few years, PDX models have
been widely established in various tumor, including gas-
tric cancer [9, 11–14]. PDX models are now becoming a
valuable tool for evaluating new anticancer drugs before
the initiation of clinical trials. The main purpose of this
study was to establish and characterize a panel of PDX
GC models, mimicking the genetic alteration of gastric
cancer patients and further use them as a platform for
the evaluation of potential targeted medicine.
Recently, Choi et al. reported the genomic fidelities of
the gastric PDX systems and identified factors correlated
with engraftment success of PDX tumors. They found
the tumor cell percentages in the implanted tissues were
correlated with higher success rates [28]. Zhang et al.
established 32 PDGCX and the genetic characters of
which were confirmed to be consistent with the original
tumors [29]. Here, a panel of 9 PDX models were
Fig. 1 Tumor growth curves of the 9 PDX models at the third
generation. The models were established subcutaneously and
median tumor volumes in 5 tumor-bearing mice from each model
are represented
Table 2 HER2,cMet, and FGFR2 statuses in a cohort of GC patients and corresponding PDX donors
Samples HER2 cMet FGFR2
OP(%) AP(%) Positive(%) OP(%) AP(%) AP(%)
IHC3+ FISH IHC /FISH IHC3+ IHC2+ IHC3+/2+ FISH FISH
A cohort of GC patients (n = 163) 12(7.3%) 5(3.1%) 17(10.4%) 7(4.3%) 25(15.3%) 32(19.6%) 7(4.3%) 6(3.7%)
Corresponding patients of PDX models (n = 32) 3(9.4%) 1(3.1%) 4(12.5%) 3(9.4%) 5(15.6%) 8(25.0%) 3(9.4%) 1(3.1%)
OP protein overexpression, AP gene amplification
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established with a success rate of 28.1%, which is similar
to previously reported data [8]. When comparing the
success rates between the first, second and third genera-
tions, we found the first implantation is a critical step in
the process, while the success rate after the third gener-
ation nearly reached 100%.No significant correlation was
observed between the engraftment achievement ratio
and patients’ clinical feature.
However, a recent study revealed that prior chemo-
therapy may reduce the engraftment achievement ratio
[30]. Indeed, patients who showed complete response
after pre-surgery chemotherapy were excluded from fur-
ther implantation in our study. A vital question of the
utility of PDX models is whether the passage of tumors
in experimental mice alters their histopathological and
molecular features. As shown above, only one model
with cMet IHC 3+/FISH(+) changed to cMet IHC 0/
FISH(-) (Additional file 2: Figure S1); the concordance
rate of Her2,cMet and FGFR2 alteration between
patients’ primary tumors and xenografts was 92.9%
(Table 3). We speculate that tumor heterogeneity may
be one of the possible cause of discordance between
PDX models and donors. Previous studies have revealed
that established PDX models are biologically stable when
passaged in mice, in terms of global gene-expression pat-
terns, mutational status, and drug responsiveness [8, 10].
Therefore, PDX models, mimicking the histopathological
and molecular features of patients, constitute a superior
Fig. 2 Representative images of IHC and FISH analyses of gastric cancer tumor tissues. Her2 and cMet expression levels were interpreted as
scores 0, 1+, 2+, and 3+, respectively. For the FISH assay, orange signals represent Her2,cMet and FGFR2, and the green ones are CEN 17/ CEN 7/
CEN10, respectively. AP, amplification
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tool for the preclinical study of new emerging targeted
therapies.
Approving trastuzumab for HER2-positive GC patients
represents a milestone in gastric cancer targeted therapy
[15]. Recently, cMet and FGFR2, two other members of
the RTK family, have been intensely investigated in
gastric cancer. A high–resolution genomic analysis of a
large cohort of gastric primary tumors revealed that
approximately 4% and 9% gastric patients harbor cMet
and FGFR2 amplification, respectively. The prevalence
rates of cMet and FGFR2 alterations in Chinese gastric
cancer patients have rarely been reported. Liu et al.
reported that nearly 6.1% and 5.1% gastric cancer
specimens harbor cMet or FGFR2 amplification in a co-
hort of Chinese gastric cancer, respectively. Here, we
simultaneously studied the status of Her2, cMet and
Fig. 3 Kaplan-Meier survival analyses of overall survival in a cohort of gastric cancer patients. a OS according to Her2 status, Her2+ (IHC3+ or FISH
+); b OS according to cMet protein expression or gene amplification; c OS according to FGFR2 gene amplification. AP, gene amplification
Table 3 Her2,cMet, and FGFR2 statuses of patients and PDX models
Patients Patients/PDX models
Models Age Stage Lauren Her2 cMet FGFR2
G01 ≥60 III Mixed -/- -/- -/-
G03 ≥60 III Mixed -/- IHC(2+)/FISH(-) FISH(+)
G05 <60 III Intestinal IHC(3+)/FISH(+) -/- -/-
G16 <60 III Intestinal -/- -/- -/-
G27 ≥60 III Diffuse -/- -/- -/-
G29 <60 III Intestinal -/- -/- -/-
G30 <60 II Intestinal -/- IHC(3+)/FISH(+) -/-
G31 <60 III Intestinal -/- IHC(2+)/FISH(+) -/-
G32 ≥60 III Diffuse -/- -/- -/-
G26a ≥60 III Intestinal IHC(2+)/FISH(-) -/- -/-
G28a <60 III Diffuse -/- -/- -/-
G21a ≥60 III Intestinal -/- -/- -/-
G22b <60 II Intestinal -/- -/- -/-
G23b ≥60 III Intestinal -/- IHC(3+/0)/FISH(+/-)c -/-
aPDX models only transplanted to the second generation; bPDX models only transplanted to the first generation; cdiscordance of cMet status between primary
tumors and xenografts in G23
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FGFR2 amplification in a cohort of Chinese GC patients
and a panel of PDX models. Our data showed cMet
overexpression and amplification in 19.6% and 4.3% of
GC patients, respectively. Survival analysis revealed that
patients with cMet protein IHC3+ or gene amplification
have a poorer survival rate, in agreement with a recent
study [24]. In addition, FGFR2 amplification was har-
boured in 3.7% GC patients. FGFR2 amplification tended
to indicate a lower survival rate, although a statistical
significance was not obtained. A recent international
multi-center study reported that FGFR2 amplification is
associated with poor prognosis in gastric cancer. Her2
positive rate was 10.4%, which was consistent with previ-
ously reported data [31].
Based on the above findings, we confirm that a signifi-
cant proportion of gastric cancer patients harbour cMet
and FGFR2 alterations, and may benefit from cMet and
FGFR2 targeted therapies. A phase I study showed that
patients with cMet-amplified gastroesophageal cancer
treated with crizotinib experience significant tumor
shrinkage [32]. In addition, a preclinical study revealed
that AZD4547 exerts marked antitumor effects on GC
xenografts carrying FGFR2 gene amplification [25]. There-
fore, cMet or FGFR2 gene amplification seems to be a po-
tential predictive biomarker for drug sensitivity; however,
there is a possible correlation between gene amplification
and protein expression as well as possible inconsistencies
between IHC data and gene amplifications in terms of
tumor take rates, growth kinetics and/or sensitivities to
the respective treatment regimens. To further evaluate the
translational significance of the above findings, the antitu-
mor efficacy of crizotinib and AZD4547 was assessed on
the panel of PDX models generated. As shown above,
PDX models with cMet and FGFR2 amplification were
highly sensitive to crizotinib, while others showed minimal
or even no response. Interestingly, we found that com-
bined treatment of crizotinib and AZD4547 enhances the
antitumor effect of AZD4547 in G03 (FGFR2-amplifed
Fig. 4 Molecular characterization of the PDX models. Immunohistochemical staining for cMet and HER2, and FISH assay for Her2,cMet and FGFR2
are shown. Immuno-detectable proteins are indicated by brown staining; nuclei are counterstained in blue. Original magnification, ×200
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Fig. 5 Antitumor efficacy of crizotinib, AZD4547 and trastuzumab in 5 PDX models. Tumor-bearing mice were treated starting from tumor volume
of 100 ~ 200 mm3. crizotinib, AZD4547, and trastuzumab were administered as described in the experimental section. Subcutaneous tumor
volumes were measured using calipers and calculated as mean ± SEM. Statistical analysis of tumor growth inhibition was performed using
Student’s t-test or one-way ANOVA. P < 0.05 was considered statistically significant. (a) Antitumor activity of crizotinib, AZD4547 or Transtuzumab
on G01 PDTX models (Her2-, cMet-, FGFR2-); (b) Antitumor activity of crizotinib, AZD4547 or combo treatment on G03 PDTX models (FGFR2+); (c)
Antitumor activity of Transtuzumab on G05 PDTX models (Her2+); (d) Antitumor activity of crizotinib on G30 PDTX models (cMet+); (e) Antitumor
activity of crizotinib on G31 PDTX models (cMet+)
Fig. 6 AZD4547 and crizotinib synergistically inhibited activation of MAPK/ERK pathway in G03 xenograft derived GC cells. GC cells derived from
G03 xenograft were treated with 200nM/L crizotinib or 30nM/L AZD4547, either alone or as a combo treatment(Cri + AZD) for 1 hour. Whole cell
lysates were collected and analyzed by western blot. Cell lysates were immunoblotted for phospho- and total protein as indicated
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and cMet non-amplified but IHC(2+)). The in vitro data
showed obvious inhibition of Erk activation by crizotinib
in the G03 derived cells, however, crizotinib monotherapy
in vivo showed no significant tumor growth inhibition
compared with the control group. There might be some
mechanism causing this discrepancy which need further
investigation. A recent study also demonstrated that
activation of several receptor tyrosine kinases (RTKs), in-
cluding EGFR, HER3 and MET, contributes to AZD4547
hyposensitivity in FGFR2 amplified GC cells, and the res-
cue effect was abrogated by inhibiting these RTKs with
their targeted tyrosine kinase inhibitors (TKIs) [33].
Another study demonstrated that FGFR is one of the
combinatorial targets to overcome resistance to cMet-
targeted therapy in gastric cancer [34]. The underlying
mechanisms for the enhanced antitumor effect by com-
bined treatment of crizotinib and AZD4547 in G03 is still
unknown. By using the G03 xenograft derived cells, in
vitro assay showed that a combination treatment of
crizotinib and AZD4547 led to synergetic inhibition of
MAPK/ERK pathway. Further biochemistry study on the
GC cell lines with different status of cMet or FGFR2 amp-
lification showed that the synergetic effect were obtained
only in cMet or FGFR2 amplified cells, we speculated that
co-targeting cMet and FGFR2 may exhibit a synergetic
tumor inhibition through MAPK/ERK pathway. We ob-
served the trans-phosphorylation of MET and FGFR2,
however, the trans-phosphorylation were not consistent in
the four cell lines(data not shown). The synergistic effect
of the combo treatment of the crizotinib and FGFR2 in-
hibitor at the level of ERK phosphorylation is consistent in
all the four different cell lines except the AGS cells which
is negative for both receptor expression. We believe that
the molecular mechanism underlying the synergistic effect
of concomitant inhibition of the two parallel pathways, is
more like to involve the downstream effectors of MET
and FGFR2, but not the transphosphorylation of the two
parallel receptors. Further studies are needed to explore
the crosstalk between cMet and FGFR2 signaling pathway.
Co-targeting cMet and FGFR2 may be a promising strat-
egy for gastric cancer patients with amplification of cMet
or FGFR2.
Conclusions
In conclusion, a panel of 9 PDX GC models were suc-
cessfully established, providing an ideal platform for the
evaluation of targeted agents. In addition, Her2, cMet
and FGFR2 statuses were profiled in a cohort of GC pa-
tients and the PDX models. Finally, our data indicate
that a significant proportion of GC patients harbouring
cMet or FGFR2 gene amplification can benefit from
cMet or FGFR2 targeted therapies or combined targeted
therapies.
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